Protease inhibitors and their peptidomimetic derivatives as potential drugs

被引:89
作者
Fear, Georgie [1 ]
Komarnytsky, Slavko [1 ]
Raskin, Ilya [1 ]
机构
[1] Rutgers State Univ, Biotech Ctr, New Brunswick, NJ 08901 USA
关键词
protease; protease inhibitors; therapeutic application; clinical trials; approved drugs;
D O I
10.1016/j.pharmthera.2006.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Precise spatial and temporal regulation of proteolytic activity is essential to human physiology. Modulation of protease activity with synthetic peptidomimetic inhibitors has proven to be clinically useful for treating human immunodeficiency virus (HIV) and hypertension and shows potential for medicinal application in cancer, obesity, cardiovascular, inflammatory, neurodegenerative diseases, and various infectious and parasitic diseases. Exploration of natural inhibitors and synthesis of peptidomimetic molecules has provided many promising compounds performing successfully in animal studies. Several protease inhibitors are undergoing further evaluation in human clinical trials. New research strategies are now focusing on the need for improved comprehension of protease-regulated cascades, along with precise selection of targets and improved inhibitor specificity. It remains to be seen which second generation agents will evolve into approved drugs or complementary therapies. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:354 / 368
页数:15
相关论文
共 148 条
[91]   RETRACTED: Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: Implications for flaviviral polyprotein processing and drug design (Retracted article. See vol. 397, pg. 1119, 2010) [J].
Murthy, HMK ;
Judge, K ;
DeLucas, L ;
Padmanabhan, R .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 301 (04) :759-767
[92]  
Nakatani K, 2001, J LEUKOCYTE BIOL, V69, P241
[93]   Membrane associated proteases and their inhibitors in tumour angiogenesis [J].
Noel, A ;
Maillard, C ;
Rocks, N ;
Jost, M ;
Chabottaux, V ;
Sounni, NE ;
Maquoi, E ;
Cataldo, D ;
Foidart, JM .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (06) :577-584
[94]   Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100) - Comparison with enalapril [J].
Nussberger, J ;
Wuerzner, G ;
Jensen, C ;
Brunner, HR .
HYPERTENSION, 2002, 39 (01) :E1-E8
[95]   Peptidomimetic inhibitors of the human cytomegalovirus protease [J].
Ogilvie, W ;
Bailey, M ;
Poupart, MA ;
Abraham, A ;
Bhavsar, A ;
Bonneau, P ;
Bordeleau, J ;
Bousquet, Y ;
Chabot, C ;
Duceppe, JS ;
Fazal, G ;
Goulet, S ;
GrandMaitre, C ;
Guse, I ;
Halmos, T ;
Lavallee, P ;
Leach, M ;
Malenfant, E ;
OMeara, J ;
Plante, R ;
Plouffe, C ;
Poirier, M ;
Soucy, F ;
Yoakim, C ;
Deziel, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (25) :4113-4135
[96]   Leucaena leucocephala serine proteinase inhibitor:: primary structure and action on blood coagulation, kinin release and rat paw edema [J].
Oliva, MLV ;
Souza-Pinto, JC ;
Batista, IFC ;
Araujo, MS ;
Silveira, VF ;
Auerswald, EA ;
Mentele, R ;
Eckerskorn, C ;
Sampaio, MU ;
Sampaio, CAM .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :64-74
[97]   Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors [J].
Olson, JE ;
Lee, GK ;
Semenov, A ;
Rosenthal, PJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (04) :633-638
[98]   Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition [J].
Ottaviani, JI ;
Actis-Goretta, L ;
Villordo, JJ ;
Fraga, CG .
BIOCHIMIE, 2006, 88 (3-4) :359-365
[99]   Tumour microenvironment - Opinion - Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy [J].
Overall, CM ;
Kleifeld, O .
NATURE REVIEWS CANCER, 2006, 6 (03) :227-239
[100]   Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B [J].
Pan, WL ;
Tan, NH ;
Zeng, GZ ;
Zhang, YM ;
Jia, RR .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (20) :5819-5825